CLN8 Polyclonal Antibody, Biotin Conjugated

Applications

  • WB
  • ELISA
  • IHC-P
  • IHC-F

Reactivity

  • Human
  • Rat

Predicted Reactivity

  • Mouse
  • Dog
  • Pig
  • Horse
  • Rabbit
Overview
Catalog # bs-11715R-Biotin
Product Name CLN8 Polyclonal Antibody, Biotin Conjugated
Applications WB, ELISA, IHC-P, IHC-F
Reactivity Human, Rat
Predicted Reactivity Mouse, Dog, Pig, Horse, Rabbit
Specifications
Conjugation Biotin
Host Rabbit
Source KLH conjugated synthetic peptide derived from human CLN8
Immunogen Range 201-286/286
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C for 12 months.
Target
Gene ID 2055
Swiss Prot Q9UBY8
Subcellular location Cytoplasm, Cell membrane
Synonyms Ceroid-lipofuscinosis, neuronal 8 epilepsy, progressive with mental retardation; Cln8; CLN8_HUMAN; EPMR; Protein CLN8; C8orf61
Background CLN8, a 286 amino acid transmembrane protein, localizes mainly to the endoplasmic reticulum, but also partially to the ER-Golgi intermediate compartment (ERGIC). Mutations in the CLN8 gene cause neuronal ceroid lipofuscinosis 8 and progressive epilepsy with mental retardation (EPMR). Both disorders are forms of neuronal ceroid-lipofuscinose (NCL), a group of progressive neurodegenerative diseases found in children, characterized by failure of psychomotor development, impaired vision, seizures and premature death. The CLN8 protein is one of eight proteins in the CLN family, including CLN1-CLN7, which are associated with NCL.
Application Dilution
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500